 |
Parkinsons News: 273 headlines |
|
|||||
Celebrity Fight Night Video  |
||||||||
|
||||||||
|
||||||||
| Sources used by our Parkinsons News Channel Research Team: | ||||||||
| The New York Times, CNN, FOX, CBS, BBC, Mayo Clinic, Johns Hopkins Medicine, UCLA Medical Center, National Institute of Health, Stanford Hospital, Memorial Sloan- Kettering, Yale Cancer Center, Massachusetts General Hospital, Brigham and Women's Hospital, University of Michigan, M. D. Anderson Cancer Center, National Institute of Health, American Cancer Association, NBC, Reuters News, American College of Cardiology, Journal of the American Medical Association & 100's more | ||||||||
| Links | ||||||||
| Barrow Neurological Institute | ||||||||
| Archives |
Thursday
Transdermal Rotigotine Well Tolerated Through 18 Months of Treatment
A once-daily treatment of the investigative dopamine agonist rotigotine (Neupro, Schwarz Pharma) in a transdermal patch is associated with sustained benefits and is well tolerated as a monotherapy in Parkinson's disease, according to investigators who presented their findings here at the American Neurological Association (ANA) 131st Annual Meeting.
In an 18-month study, the investigators found that "the rotigotine transdermal patch was generally safe and well tolerated, with a low rate of discontinuance due to adverse effects," principal investigator Ray L. Watts, MD, chair of the department of neurology at the University of Alabama at Birmingham, said in a presentation. "We think that use of the patch can help a person with early-stage Parkinson's disease [delay using] levodopa for 2 to 3 years," he said.....
A once-daily treatment of the investigative dopamine agonist rotigotine (Neupro, Schwarz Pharma) in a transdermal patch is associated with sustained benefits and is well tolerated as a monotherapy in Parkinson's disease, according to investigators who presented their findings here at the American Neurological Association (ANA) 131st Annual Meeting.
In an 18-month study, the investigators found that "the rotigotine transdermal patch was generally safe and well tolerated, with a low rate of discontinuance due to adverse effects," principal investigator Ray L. Watts, MD, chair of the department of neurology at the University of Alabama at Birmingham, said in a presentation. "We think that use of the patch can help a person with early-stage Parkinson's disease [delay using] levodopa for 2 to 3 years," he said.....